

Hypertonie: Wann und wie soll man eine sekundäre Ätiologie abklären?

Hypertension: quand rechercher une étiologie secondaire?

Literatur / Références

1. US-Burden-of-Disease-Collaborators. The state of us health, 1990–2010: Burden of diseases, injuries, and risk factors. *JAMA*. 2013;310(6):591–608.
2. Prague JK, May SWhitelaw BC. Cushing's syndrome. *BMJ*. 2013;346.
3. Ribeiro-Oliveira Jr A Barkan A. The changing face of acromegaly[mdash]advances in diagnosis and treatment. *Nat Rev Endocrinol*. 2012;8(10):605–611.
4. Clair M, Fernandes SM, Khairy P, Graham DA, Krieger EV, Opatowsky AR, et al. Aortic Valve Dysfunction and Aortic Dilation in Adults with Coarctation of the Aorta. *Congenital Heart Disease*. 2013;n/a-n/a.
5. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Journal of Hypertension*. 2013;31(7):1281–1357 10.1097/01.hjh.0000431740.32696.cc.
6. Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi CVolpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. *J Hum Hypertens*. 2013.
7. Boateng FK Greco BA. Renal Artery Stenosis: Prevalence of, Risk Factors for, and Management of In-Stent Stenosis. *American Journal of Kidney Diseases*. 2013;61(1):147–160.
8. Persu A, Touzé E, Mousseaux E, Barral X, Joffre FPlouin P-F. Diagnosis and management of fibromuscular dysplasia: an expert consensus. *European Journal of Clinical Investigation*. 2012;42(3):338–347.
9. Safak E, Wilke C, Derer W, Busjahn A, Gross M, Moeckel M, et al. Long-term follow-up of patients with atherosclerotic renal artery disease. *Journal of the American Society of Hypertension*. 2013;7(1):24–31.
10. Drieghe B, Madaric J, Sarno G, Manoharan G, Bartunek J, Heyndrickx GR, et al. Assessment of renal artery stenosis: side-by-side comparison of angiography and duplex ultrasound with pressure gradient measurements. *European Heart Journal*. 2008;29(4):517–524.
11. Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, et al. The United States Registry for Fibromuscular Dysplasia: Results in the First 447 Patients. *Circulation*. 2012;125(25):3182–3190.
12. Slovut DP Olin JW. Fibromuscular Dysplasia. *New England Journal of Medicine*. 2004;350(18):1862–1871.
13. Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering Syndrome. *European Heart Journal*. 2011;32(18):2231–2235.
14. Williams GJ, Macaskill P, Chan SF, Karplus TE, Yung W, Hodson EM, et al. Comparative Accuracy of Renal Duplex Sonographic Parameters in the Diagnosis of Renal Artery Stenosis: Paired and Unpaired Analysis. *American Journal of Roentgenology*. 2007;188(3):798–811.
15. Galati S-J, Hopkins SM, Cheesman KC, Zhuk RALevine AC. Primary aldosteronism: emerging trends. *Trends in Endocrinology & Metabolism*. 2013(0):421–430.
16. Rossi GP. Diagnosis and Treatment of Primary Aldosteronism. *Endocrinology and Metabolism Clinics of North America*. 2011;40(2):313–332.
17. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism. *Hypertension*. 2002;40(6):897–902.
18. Küpers EM, Amar L, Raynaud A, Plouin P-FSteichen O. A Clinical Prediction Score to Diagnose Unilateral Primary Aldosteronism. *Journal of Clinical Endocrinology & Metabolism*. 2012;97(10):3530–3537.
19. Harvey A, Pasiaka JL, Kline GSo B. Modification of the protocol for selective adrenal venous sampling results in both a significant increase in the accuracy and necessity of the procedure in the management of patients with primary hyperaldosteronism. *Surgery*. 2012;152(4):643–651.
20. Kaplan N. Primary aldosteronism: A contrarian view. *Reviews in Endocrine and Metabolic Disorders*. 2011;12(1):49–52.
21. Lenders JWM, Eisenhofer G, Mannelli MPacak K. Pheochromocytoma. *The Lancet*. 2005;366(9486):665–675.
22. Mannelli M, Lenders JWM, Pacak K, Parenti GEisenhofer G. Subclinical pheochromocytoma. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2012;26(4):507–515.
23. Reisch N, Walz MK, Erlic ZNeumann HPH. Das Phäochromozytom – noch immer eine Herausforderung. *Der Internist*. 2009;50(1):27–35.
24. Grouzmann E Lamine F. Determination of catecholamines in plasma and urine. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2013(0):(in press).

25. Kunstman JW, Kirsch JD, Mahajan AU, Delaman R. Parathyroid Localization and Implications for Clinical Management. *Journal of Clinical Endocrinology & Metabolism*. 2013;98(3):902–912.
26. Danzi S, Klein I. Thyroid Hormone and the Cardiovascular System. *Medical Clinics of North America*. 2012;96(2):257–268.
27. Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: A Secondary Cause of Isolated Systolic Hypertension. *The Journal of Clinical Hypertension*. 2006;8(8):596–599.
28. Stabouli S, Papakatsika S, Kotsis V. Hypothyroidism and hypertension. *Expert Review of Cardiovascular Therapy*. 2010;8(11):1559–1565.
29. Mazza A, Beltramello G, Armigliato M, Montemurro D, Zorzan Z, Zui nM, et al. Arterial hypertension and thyroid disorders: What is important to know in clinical practice? . *Ann Endocrinol (Paris)*. 2011;72:296–303.
30. Grossman E, Messerli FH. Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension. *The American Journal of Medicine*. 2012;125(1):14–22.
31. Vanberg P, Atar D. Androgenic Anabolic Steroid Abuse and the Cardiovascular System, in *Doping in Sports: Biochemical Principles, Effects and Analysis*, Thieme D and Hemmersbach P, Editors. 2010, Springer Berlin Heidelberg. p. 411–457.
32. Chignalia AZ, Schuldt EZ, Camargo LL, Montezano AC, Callera GE, Laurindo FR, et al. Testosterone Induces Vascular Smooth Muscle Cell Migration by NADPH Oxidase and c-Src-Dependent Pathways. *Hypertension*. 2012;59(6):1263–1271.
33. Brennan BP, Kanayama G, Pope HG. Performance-Enhancing Drugs on the Web: A Growing Public-Health Issue. *The American Journal on Addictions*. 2013;22(2):158–161.
34. Montesi SB, Bajwa EK, Malhotra A. Biomarkers of sleep apnea. *CHEST Journal*. 2012;142(1):239–245.
35. Montesi SB, Edwards BA, Malhotra AB, Bakker JP. The Effect of Continuous Positive Airway Pressure Treatment on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Clin Sleep Med* 2012;15:587–596.
36. Simon S, Collop N. Latest advances in sleep medicine: Obstructive sleep apnea. *CHEST Journal*. 2012;142(6):1645–1651.
37. Damy T, Margarit L, Noroc A, Bodez D, Guendouz S, Boyer L, et al. Prognostic impact of sleep-disordered breathing and its treatment with nocturnal ventilation for chronic heart failure. *European Journal of Heart Failure*. 2012;14(9):1009–1019.
38. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. *J Hum Hypertens*. 2012;26(5):281–287.
39. Kasai T, Floras JS, Bradley TD. Sleep Apnea and Cardiovascular Disease: A Bidirectional Relationship. *Circulation*. 2012;126(12):1495–1510.
40. Marin JM, Agustí A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. *JAMA*. 2012;307(20):2169–2176.
41. Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, et al. Recommendations for the management of patients with obstructive sleep apnoea and hypertension. *European Respiratory Journal*. 2013;41(3):523–538.
42. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. *Am J Hypertens* 2006;19:1190–1196.
43. Dufaux B, Agius R, Nadulski T, Kahl H-G. Comparison of urine and hair testing for drugs of abuse in the control of abstinence in driver's license re-granting. *Drug Testing and Analysis*. 2012;4(6):415–419.